Vicken Karageozian, MD, president and chief medical officer, Allegro Ophthalmics, shares how Allegro has “taken a lot of risk out of the equation” after reporting results from the DEL MAR Phase IIb clinical trial that evaluated Luminate (ALG-1001) in 136 patients with diabetic macular edema (DME). Luminate met its primary and secondary endpoints, demonstrating promising visual acuity gains and a reduction in central macular thickness (CMT) that were equivalent to bevacizumab monotherapy. Karageozian also shines a light on Allegro’s promising pipeline.
Vicken Karageozian, MD
Vicken Karageozian, MD, is president and chief medical officer of Allegro Ophthalmics. Dr. Karageozian has more than 22 years’ experience building and leading companies in the ophthalmic pharmaceutical space.